NCT06717269

A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948

Recruiting now Phase 1 Last updated 3 February 2026

What this trial tests

Phase 1 trial testing NX-5948 in Healthy Volunteer in 18 participants. Currently enrolling.

Timeline

30 November 2024

Primary endpoint
1 April 2026

1 August 2026

Quick facts

Lead sponsor	Nurix Therapeutics, Inc.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	30 November 2024
Primary completion	1 April 2026
Estimated completion	1 August 2026
Sites	1 location across United States

Drugs / interventions tested

• NX-5948 — full drug profile →
• Esomeprazole (esomeprazole) — full drug profile →

Conditions studied

• Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Nurix Therapeutics, Inc. — full company profile →

Who can join

Adults 19 to 55, any sex, with Healthy Volunteer. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Assessment of PK parameters: NX-5948 tablets versus capsules
  Time frame: 9 weeks
  Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (AUC)
• Assessment of PK parameters: NX-5948 tablets versus capsules
  Time frame: 9 weeks
  Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Cmax)
• Assessment of PK parameters NX-5948 tablets versus capsules
  Time frame: 9 weeks
  Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Tmax)
• Food effect and effect of esomeprazole on AUC0-t for single-dose NX-5948 tablet
  Time frame: 9 weeks
  Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet
• Food effect and effect of esomeprazole on AUC0-inf for single-dose NX-5948 tablet
  Time frame: 9 weeks
  Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet
• Food effect and effect of esomeprazole on Cmax for single-dose NX-5948 tablet
  Time frame: 9 weeks
  Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet

Sponsor's own description

This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders.
   Ma Z, Zhou J. · · 2025 · cited 28× · PMID 40702893 · DOI 10.1021/acs.jmedchem.5c01818
2. Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
   Fan G, Chen S, Zhang Q, Yu N, et al · · 2025 · cited 6× · PMID 41049269 · DOI 10.1002/mco2.70401
3. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.
   Knoll N, Neamati N, Üren A. · · 2026 · PMID 41988372 · DOI 10.1021/acsptsci.5c00730
4. Prospects and advances of PROTAC in the treatment of hematologic malignancies.
   Wang X, Zhang M, Mei H. · · 2026 · PMID 41845415 · DOI 10.1186/s40164-026-00759-3
5. PROTAC-based protein degradation: a window of opportunity for melanoma therapy.
   Gentile G, D'Aguanno S, Di Martile M, Petricca A, et al · · 2026 · PMID 41761284 · DOI 10.1186/s12929-026-01225-2